5 Key Takeaways
-
1
Evidence-based myopia management is essential for young patients, yet significant scientific questions remain regarding treatment efficacy and candidate selection.
-
2
Current myopia control trials primarily involve young patients, with specific age and refraction parameters limiting generalizability of findings.
-
3
Atropine and orthokeratology show efficacy in myopia control, but unknowns persist regarding treatment effects for patients outside established criteria.
-
4
Adult-onset myopia is prevalent, with 15% of adults developing myopia in their 20s, yet research on its management remains limited.
-
5
Monitoring retinal health is crucial for adult myopes, as certain fundus characteristics may indicate risk for future myopic macular degeneration.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.